CSN1S1

Across TCGA pan-cancer cohorts, CSN1S1 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CSN1S1 data layer compared with 21 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher CSN1S1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CSN1S1 expression acts as an unfavorable survival marker.

LIHC, LUAD, and COAD are the cancer types where CSN1S1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	III,IV	0.076	0.360	.001	24	view →
LUAD	OS	Median	II,III,IV	0.079	0.709	<.001	21	view →
COAD	DFS	Median	All	0.027	0.795	<.001	19	view →
BLCA	OS	Median	III,IV	0.153	0.655	.011	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
ACC	DFS	Median	All	0.140	0.666	.049	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CSN1S1–LIHC (DFS)

Open the LIHC breakdown →